Bimatoprost - Allergan

Drug Profile

Bimatoprost - Allergan

Alternative Names: AGN-024; AGN-192024; Bimatoprost SR; Bimatoprost Sustained-Release Implant; BUDPF; Glash Vista Cutaneous Solution 0.03%; GlashVista; Latisse; Lumigan; LumiganRC; LumiganX; preservative-free bimatoprost

Latest Information Update: 15 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Developer Allergan; Senju Pharmaceutical
  • Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Hypotrichosis; Ocular hypertension
  • Phase II Alopecia

Most Recent Events

  • 13 Jun 2018 Allergan announces intention to submit NDA to US FDA for open-angle glaucoma or ocular hypertension in the second half of 2019
  • 13 Jun 2018 Efficacy and adverse events data from a phase III trial in Glaucoma and Ocular hypertension released by Allergan
  • 15 Mar 2017 Allergan terminates a phase I trial for Alopecia in USA (NCT02676310)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top